<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS107254</article-id>
<article-id pub-id-type="doi">10.1101/2020.11.17.385500</article-id>
<article-id pub-id-type="archive">PPR239461</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Rappazzo</surname>
<given-names>C. Garrett</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Tse</surname>
<given-names>Longping V.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaku</surname>
<given-names>Chengzi I.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wrapp</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sakharkar</surname>
<given-names>Mrunal</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Deli</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deveau</surname>
<given-names>Laura M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yockachonis</surname>
<given-names>Thomas J.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herbert</surname>
<given-names>Andrew S.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Battles</surname>
<given-names>Michael B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Brien</surname>
<given-names>Cecilia M.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Michael E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geoghegan</surname>
<given-names>James C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Belk</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Linghang</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Linlin</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scobey</surname>
<given-names>Trevor D.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burton</surname>
<given-names>Dennis R.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nemazee</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dye</surname>
<given-names>John M.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Voss</surname>
<given-names>James E.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gunn</surname>
<given-names>Bronwyn M.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McLellan</surname>
<given-names>Jason S.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baric</surname>
<given-names>Ralph S.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A11">11</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gralinski</surname>
<given-names>Lisa E.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>Laura M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A12">12</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Adimab LLC, Lebanon, NH 03766, USA</aff>
<aff id="A2">
<label>2</label>Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA</aff>
<aff id="A3">
<label>3</label>Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA</aff>
<aff id="A4">
<label>4</label>Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA</aff>
<aff id="A5">
<label>5</label>Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA</aff>
<aff id="A6">
<label>6</label>U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA</aff>
<aff id="A7">
<label>7</label>The Geneva Foundation, 917 Pacific Avenue, Tacoma, WA 98402, USA</aff>
<aff id="A8">
<label>8</label>IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA</aff>
<aff id="A9">
<label>9</label>Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA</aff>
<aff id="A10">
<label>10</label>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA</aff>
<aff id="A11">
<label>11</label>Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA</aff>
<aff id="A12">
<label>12</label>Adagio Therapeutics, Inc., Waltham, MA 02451, USA</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding authors. <email>rbaric@email.unc.edu</email> (R.S.B.); <email>lgralins@email.unc.edu</email> (L.E.G.); <email>laura.walker@adimab.com</email> (L.M.W.).</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>11</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>17</day>
<month>11</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. Here, we employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains (RBDs) and neutralizes representative epidemic sarbecoviruses with remarkable potency. Structural and biochemical studies demonstrate that ADG-2 employs a unique angle of approach to recognize a highly conserved epitope overlapping the receptor binding site. In murine models of SARS-CoV and SARS-CoV-2 infection, passive transfer of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate for the treatment and prevention of SARS-CoV-2 and future emerging SARSlike CoVs.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">Over the past two decades, three pathogenic CoVs have emerged from zoonotic reservoirs to cause outbreaks of deadly pneumonia in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (<xref ref-type="bibr" rid="R1">1</xref>). SARS-CoV emerged in 2002 in the Guangdong province of China and infected ~8000 people with a case fatality rate of ~10% before being contained by public health measures (<xref ref-type="bibr" rid="R2">2</xref>). MERS-CoV emerged in the human population in 2012 and is still a significant public health threat in the Middle East (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>). In late 2019, SARS-CoV-2 emerged in the city of Wuhan in China’s Hubei province and rapidly caused an ongoing pandemic that has resulted in over a million deaths while disrupting the global economy (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R5">5</xref>). Currently, there are no approved vaccines to prevent SARS-CoV-2 infection and only one antiviral drug has been approved to treat SARS-CoV-2 associated disease (i.e. COVID19). Furthermore, the recurrent zoonotic spillover of CoVs into the human population, along with the broad diversity of SARS-like CoVs circulating in animal reservoirs (<xref ref-type="bibr" rid="R6">6</xref>), suggests that novel pathogenic CoVs are likely to emerge in the future and underscores the need for broadly active countermeasures.</p>
<p id="P3">Similar to other CoVs, the SARS-CoV-2 spike (S) protein mediates viral entry and is the only known target for neutralizing antibodies (nAbs). The S glycoprotein consists of two functional subunits, S1 and S2, that mediate receptor binding and viral fusion, respectively.</p>
<p id="P4">Previous studies have shown that the vast majority of potent neutralizing antibodies induced by natural CoV infection target the RBD on the S1 subunit (<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R10">10</xref>). Although SARS-CoV and SARS-CoV-2 both belong to the sarbecovirus subgenus and their S glycoproteins share 76% amino acid identity, only a handful of cross-neutralizing antibodies have been described to date (<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R13">13</xref>). These rare broadly neutralizing antibodies (bnAbs) represent an attractive opportunity for therapeutic drug stockpiling to prevent or mitigate future outbreaks of SARS-related CoVs, but their limited neutralization potency may translate into suboptimal protective efficacy or impractical dosing regimens. Here, we show that such bnAbs can be engineered for improved neutralization potency while retaining neutralization breadth, and we demonstrate that these bnAbs can provide broad protection <italic>in vivo</italic>.</p>
<p id="P5">We recently isolated several antibodies from the memory B cells of a 2003 SARS survivor that cross-neutralize multiple SARS-related viruses with relatively modest potency (<xref ref-type="bibr" rid="R11">11</xref>). Although breadth and potency are often opposing characteristics, we sought to engineer these bnAbs for improved neutralization potency against SARS-CoV-2, while also maintaining or improving neutralization breadth and potency against other SARS-related viruses. Because binding affinity and neutralization potency are generally well-correlated (<xref ref-type="bibr" rid="R14">14</xref>), we employed yeast-surface display technology to improve the binding affinities of three of the bnAbs (ADI55688, ADI-55689, and ADI-56046) for a prefusion-stabilized SARS-CoV-2 S protein (<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref>).</p>
<p id="P6">Yeast display libraries were generated by introducing diversity into the heavy (HC)- and light-chain (LC) variable genes of ADI-55688, ADI-55689, and ADI-56046 through oligonucleotide-based mutagenesis and transformation into <italic>Saccharomyces cerevisiae</italic> by homologous recombination (<xref ref-type="bibr" rid="R15">15</xref>). Following four rounds of selection with a recombinant SARSCoV-2 S1 protein, improved binding populations were sorted, and between 20 and 50 unique clones from each lineage were screened for binding to SARS-CoV-2 S (<xref ref-type="bibr" rid="R17">17</xref>) (<xref ref-type="fig" rid="F1">Fig. 1A, B</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1</xref>). The highest affinity binders from each of the three lineages bound to the SARS-CoV-2 S protein with monovalent equilibrium dissociation constants (K<sub>D</sub>s) in the picomolar range, representing 25 to 630-fold improvements in binding relative to their respective parental clones (<xref ref-type="fig" rid="F1">Fig. 1B</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>). To determine whether the improvements in SARS-CoV-2 S binding affinity translated into enhanced neutralization potency, we selected between 9 and 14 affinitymatured progeny from each lineage, and evaluated them for SARS-CoV-2 neutralizing activity in a murine leukemia virus (MLV) pseudovirus assay (<xref ref-type="bibr" rid="R18">18</xref>). We also measured the neutralizing activities of several clinical-stage neutralizing antibodies (nAbs) (S309, REGN10933, REGN10987, and CB6/LY-CoV016) as benchmarks (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>). All of the affinity-matured antibodies showed improved neutralizing activity relative to their parental clones, and the most potent neutralizers from each lineage (ADG-1, ADG-2, and ADG-3) displayed neutralization IC<sub>50</sub>s that were comparable to or lower than those observed for the clinical SARS-CoV-2 nAb controls (<xref ref-type="fig" rid="F1">Fig. 1B</xref>).</p>
<p id="P7">Because <italic>in vitro</italic> engineering can lead to polyspecificity with potential risks of off-target binding and accelerated clearance <italic>in vivo (<xref ref-type="bibr" rid="R21">21</xref>)</italic>, we assessed the polyspecificity of ADG-1, ADG2, and ADG-3 using a previously described assay that has been shown to be predictive of serum half-life in humans (<xref ref-type="bibr" rid="R22">22</xref>). All three antibodies lacked polyreactivity in this assay, indicating a low risk for poor pharmacokinetic behavior (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>). The three antibodies also showed low hydrophobicity, a low propensity for self-interaction, and thermal stabilities within the range observed for clinically approved antibodies (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>). In summary, the process of <italic>in vitro</italic> engineering did not negatively impact biophysical properties that are often linked to downstream behaviors such as serum half-life, ease of manufacturing, ability to formulate to high concentrations, and long-term stability.</p>
<p id="P8">To determine whether the process of SARS-CoV-2 affinity engineering impacted neutralization breadth, we evaluated ADG-1, ADG-2, and ADG-3, as well as their respective parental antibodies, for neutralizing activity against a panel of representative authentic clade I sarbecoviruses (SARS-CoV, SHC014, SARS-CoV-2, and WIV-1). Consistent with the MLVSARS-CoV-2 assay results, ADG-2 displayed highly potent neutralizing activity against authentic SARS-CoV-2, with an IC<sub>50</sub> comparable to or lower than that observed for the benchmark SARS-CoV-2 nAbs (<xref ref-type="fig" rid="F1">Fig. 1C</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>). Furthermore, in contrast to the benchmark nAbs, ADG-2 displayed high neutralization potency against SARS-CoV and the two SARSrelated bat viruses, with IC<sub>50</sub>s between 4 and 8 ng/mL (<xref ref-type="fig" rid="F1">Fig. 1C</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>). ADG-3 and the clinical nAb S309 also cross-neutralized all four sarbecoviruses, but with markedly lower potency than ADG-2. Finally, ADG-1 potently neutralized SARS-CoV-2, SARS-CoV, and WIV1, but it lacked activity against SHC014.</p>
<p id="P9">Based on its potent cross-neutralization and favorable biophysical properties, we selected ADG-2 as a lead therapeutic candidate and confirmed its potent neutralizing activity in two alternative authentic SARS-CoV-2 neutralization assays (IC<sub>50</sub> ~1 ng/mL) (<xref ref-type="fig" rid="F1">Fig. 1C, D</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>). Interestingly, ADG-2, CB6/LY-CoV016, REGN10987 and REGN10933 reached 100% neutralization on both Vero and HeLa-hACE2 target cells in this assay, whereas S309 showed complete neutralization on Vero target cells but plateaued at approximately 40% neutralization on HeLa-hACE2 target cells (<xref ref-type="fig" rid="F1">Fig. 1D</xref>). S309 also failed to neutralize MLV-SARS-CoV-2 on HeLa-hACE2 target cells (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The reason for this is unclear but may relate to glycan heterogeneity within the S309 epitope (<xref ref-type="bibr" rid="R12">12</xref>) coupled with differences in receptor expression or protease cleavage efficiency between the two types of target cells (<xref ref-type="bibr" rid="R23">23</xref>). Because SARS-CoV-2 D614G has emerged as the dominant pandemic strain (<xref ref-type="bibr" rid="R24">24</xref>), we also evaluated ADG-2 for neutralizing activity against this variant in the MLV pseudovirus assay. As expected, based on the location of the D614G substitution outside of the RBD, ADG-2 neutralized the D614G variant with equivalent potency as wild-type (WT) SARS-CoV-2 (<xref ref-type="supplementary-material" rid="SD1">Fig. S5</xref>).</p>
<p id="P10">We further assessed the breadth of sarbecovirus recognition by ADG-2 by measuring its apparent binding affinity (K<sub>D</sub>
<sup>App</sup>) to a panel of 17 representative sarbecovirus RBDs expressed on the surface of yeast (<xref ref-type="bibr" rid="R25">25</xref>). Thirteen viruses were selected from clade I — representing the closest known relatives of SARS-CoV-2 (GD-Pangolin and RaTG13) to the most divergent (SHC014 and Rs4231) — as well as four viruses from the distantly related clades 2 and 3, which do not utilize ACE2 as a host receptor (<xref ref-type="bibr" rid="R26">26</xref>) (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Recombinant hACE2-Fc and the benchmark SARS-CoV-2 nAbs described above were also included as controls. Consistent with previous reports (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R25">25</xref>), hACE2 only recognized clade I RBDs and bound with higher affinity to SARS-CoV-2 than SARS-CoV (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). In addition, the benchmark SARS-CoV-2 nAbs CB6/LYCoV016, REGN10987, and REGN10933 bound to the SARS-CoV-2 RBD with K<sub>D</sub>
<sup>Apps</sup> comparable to published reports (<xref ref-type="fig" rid="F2">Fig. 2B</xref>) (<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>). Notably, S309 displayed diminished binding in this expression platform, likely due to recognition of an epitope containing an N-glycan that may be hyper-mannosylated in yeast (<xref ref-type="bibr" rid="R12">12</xref>).</p>
<p id="P11">Consistent with their broadly neutralizing activities, S309, ADG-2, and ADG-3 displayed remarkably broad binding reactivity to clade I sarbecovirus RBDs, with ADG-2 and ADG-3 strongly binding 12/13 viruses and S309 binding all 13 (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). In contrast, ADG-1 only bound to 9/13 viruses and CB6/LY-CoV016, REGN10987, and REGN10933 bound only the closest evolutionary neighbor(s) of SARS-CoV-2, consistent with their narrow neutralization profiles (<xref ref-type="fig" rid="F2">Fig. 2B</xref> and <xref ref-type="fig" rid="F1">Fig. 1C</xref>). Importantly, ADG-2 bound with high affinity (K<sub>D</sub>
<sup>App</sup> 0.24-1.12 nM) to every clade I sarbecovirus RBD that exhibited detectable hACE2 binding in our assay. This finding supports the high degree of ADG-2 epitope conservation among sarbecoviruses that use hACE2 as a receptor.</p>
<p id="P12">Several recent studies have shown that RBD mutants that are resistant to commonly elicited SARS-CoV-2 nAbs are circulating at low levels in the human population (<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R27">27</xref>). We therefore sought to assess the breadth of ADG-2 binding to naturally circulating SARS-CoV-2 variants that contain single point mutations in the RBD. ADG-1, ADG-3, and the benchmark SARS-CoV-2 nAbs were also included as comparators. Using the yeast surface-display platform described above, we expressed the 30 most frequently observed SARS-CoV-2 RBD variants reported in the GISAID database as well as six naturally circulating SARS-CoV-2 variants that have been shown to be resistant to previously described SARS-CoV-2 nAbs (<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R28">28</xref>). One or more of the 36 SARS-CoV-2 variants exhibited loss of binding to ADG-1, CB6/LY-CoV016, REGN10987, and REGN10933, as defined by &gt;75% loss relative to the WT construct (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). Notably, the loss-of-binding variants identified for REGN10987 and REGN10933 partially overlapped with those identified in previous <italic>in vitro</italic> neutralization escape studies, validating the use of RBD display for the prediction of antibody escape mutations (<xref ref-type="bibr" rid="R29">29</xref>). In contrast, ADG-2, ADG-3, and S309 bound to all 36 variants at levels ≥50% of WT SARS-CoV-2 (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). This result, combined with the remarkable neutralization breadth observed for these three mAbs (<xref ref-type="fig" rid="F1">Fig. 1C</xref> and <xref ref-type="fig" rid="F2">Fig. 2B, D</xref>), suggests a potential link between epitope conservation and resistance to viral escape.</p>
<p id="P13">To gain further insight into the antigenic surface recognized by ADG-2, we generated a mutagenized yeast surface-display RBD library and performed rounds of selection to identify RBD variants that exhibited loss of binding to ADG-2 relative to the WT construct (<xref ref-type="fig" rid="F3">Fig. 3A</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S6A, B</xref>). To exclude mutations that globally disrupt the conformation of the RBD, a final round of positive selection was performed using a mixture of recombinant hACE2 and two RBDdirected mAbs (S309 and CR3022) that target non-overlapping epitopes distinct from the ADG-2 binding site (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R30">30</xref>) (<xref ref-type="supplementary-material" rid="SD1">Fig. S6B</xref>, and <xref ref-type="supplementary-material" rid="SD1">Fig. S7</xref>). Selected RBD mutants encoding single amino acid substitutions were individually tested for binding to ADG-2, recombinant hACE2, CR3022, and S309 to confirm site-specific knock-down mutations (<xref ref-type="supplementary-material" rid="SD1">Fig. S6C</xref>). Substitutions at only four RBD positions specifically abrogated ADG-2 binding: D405E, G502E/R/V, G504A/D/R/S/V and Y505C/N/S (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). These four residues are highly conserved among the clade I sarbecovirus subgenus and invariant among SARS-CoV-1, SARS-CoV-2, SHC014 and WIV1 viruses (<xref ref-type="fig" rid="F3">Fig. 3C</xref>), providing a molecular explanation for the breadth of binding and neutralization exhibited by ADG-2. Consistent with the conservation of these residues among clade I sarbecoviruses, none of the substitutions that impacted ADG-2 binding were present in full-length SARS-CoV-2 sequences deposited in the GISAID database as of October 19, 2020. In addition, 3 of the 4 identified mutations that abrogate ADG-2 binding lie within the hACE2 binding site (<xref ref-type="bibr" rid="R31">31</xref>) and at least one mutation at each position (G502E/R/V, G504V and Y505C/N/S) also abrogated hACE2 binding (<xref ref-type="fig" rid="F3">Fig. 3B</xref>), likely accounting for their absence among circulating SARS-CoV-2 isolates. These results suggest that the evolutionary conservation of the ADG-2 epitope is likely directly linked to ACE2 binding.</p>
<p id="P14">To support the results of this experiment, we performed low-resolution cryogenic electron microscopy (cryo-EM) of the complex of ADG-2 bound to prefusion-stabilized SARS-CoV-2 S. This yielded a ~6Å resolution 3D reconstruction that clearly had at least one ADG-2 Fab bound to an RBD in the up conformation and allowed us to unambiguously dock in previously determined high-resolution models of the SARS-CoV-2 spike and a homologous Fab (<xref ref-type="fig" rid="F3">Fig. 3D</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S8A-D</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Consistent with our fine epitope mapping and competitive binding experiments (<xref ref-type="fig" rid="F3">Fig. 3B</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S7C</xref>), the epitope recognized by ADG-2 overlaps with the hACE2-binding site and each position identified by epitope mapping clustered to the cleft between the heavy and light chains of ADG-2 (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). This epitope also partially overlaps with those recognized by frequently observed “class 1” SARS-CoV-2 nAbs, which are exemplified by <italic>VH3-53</italic> antibodies with short CDRH3s and compete with hACE2 in the RBD “up” conformation (<xref ref-type="bibr" rid="R32">32</xref>) (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). However, in contrast to previously reported nAbs in this class, ADG-2 binds with a divergent angle of approach and displays broadly neutralizing activity (<xref ref-type="bibr" rid="R32">32</xref>) (<xref ref-type="fig" rid="F3">Fig. 3E</xref>, <xref ref-type="fig" rid="F1">Fig. 1C</xref>, and <xref ref-type="supplementary-material" rid="SD1">Fig. S8E</xref>). Thus, ADG-2 binds to a highly conserved motif via a unique angle of approach, providing additional structural insight into its broad recognition of SARS-like CoVs.</p>
<p id="P15">Because Fc-mediated effector functions can contribute to protection independently of viral neutralization, we next assessed the ability of ADG-2 to induce antibody-dependent natural killer cell activation and degranulation (ADNKDA), antibody-dependent cellular phagocytosis (ADCP) mediated by monocytes and neutrophils, and antibody-mediated complement deposition (ADCD) using previously described <italic>in vitro</italic> assays (<xref ref-type="bibr" rid="R33">33</xref>). Benchmark SARS-CoV-2 nAbs S309 and REGN10987 were also included as comparators. ADG-2 displayed a highly polyfunctional profile, resulting in the induction of phagocytosis by monocytes and neutrophils, deposition of the complement component C3, and induction of NK cell degranulation (a surrogate marker of ADCC) and activation (<xref ref-type="fig" rid="F4">Fig. 4</xref>). Interestingly, while ADG-2, S309, and REGN10957 showed comparable recruitment of phagocytosis (<xref ref-type="fig" rid="F4">Fig. 4B</xref>), these antibodies differed with respect to complement deposition and NK cell activation (<xref ref-type="fig" rid="F4">Fig. 4A, C</xref>); S309 showed reduced complement deposition compared with ADG-2 and REGN10987, and ADG-2 showed superior NK cell activation over both S309 and REGN10987 (<xref ref-type="fig" rid="F4">Fig.4</xref>). In summary, ADG-2 robustly triggers diverse Fc-mediated effector activities with potencies comparable or superior to those of current lead SARS-CoV-2 clinical antibodies. However, it should be noted that the contribution of extraneutralizing activities to protection against SARS-CoV-2 is currently unknown and may vary among different antibody specificities.</p>
<p id="P16">Finally, we tested the ability of ADG-2 to provide broad <italic>in vivo</italic> protection in immunocompetent mouse models of SARS and COVID-19 using mouse-adapted SARS-CoV (MA15)- and SARS-CoV-2 (MA10), respectively (<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R35">35</xref>). Balb/c mice were prophylactically treated with either 200 μg of ADG-2 or PBS via IP injection 12 hours prior to intranasal challenge with a 10<sup>3</sup> PFU dose of MA15 or MA10. All mice were monitored daily for weight loss and changes in respiratory function and groups of mice were euthanized at day two or four post-infection to allow for measurement of virus replication in the lung and analysis of lung histopathology. We observed substantial, progressive weight loss in sham-treated mice infected with both viruses along with increases in Penh, a calculated measure of airway resistance (<xref ref-type="bibr" rid="R35">35</xref>). In contrast, mice treated prophylactically with ADG-2 demonstrated minimal weight loss, no change in Penh and no signs of gross pathology at the time of harvest (<xref ref-type="fig" rid="F5">Fig. 5A, B</xref>). Furthermore, prophylactic antibody treatment prevented viral replication in the lungs at both two and four days post-infection (dpi). We next investigated the ability of ADG-2 to act anti-virally against SARSCoV-2 MA10 in a therapeutic setting. Mice were treated with 200 μg of ADG-2 or PBS 12 hours following intranasal challenge with a 10<sup>3</sup> PFU dose of MA10. Mice given therapeutic ADG-2 had intermediate levels of weight loss, moderate respiratory function changes and some gross lung pathology; significantly more than prophylactically-treated mice but significantly less than sham-treated mice (<xref ref-type="fig" rid="F5">Fig. 5C</xref>). Therapeutic antibody treatment also resulted in a significant reduction in lung viral loads at four dpi, but not at two dpi, relative to sham-treated mice. We conclude that ADG-2 treatment can reduce disease burden in mice infected with both SARSCoV MA15 and SARS-CoV-2 MA10.</p>
<p id="P17">Since the beginning of the COVID-19 pandemic, a plethora of potently neutralizing SARS-CoV-2 antibodies have been isolated, and some have rapidly advanced into clinical trials (<xref ref-type="bibr" rid="R36">36</xref>). However, the epitopes recognized by most of these nAbs are highly variable among other clade 1a and 1b sarbecoviruses, hence limiting their neutralization breadth and increasing their susceptibility to antibody escape mutations (<xref ref-type="bibr" rid="R27">27</xref>). Here, we described an engineered antibody that neutralizes SARS-CoV-2 with a potency that rivals current lead SARS-CoV-2 clinical nAbs, but also broadly neutralizes other clade I sarbecoviruses, potently triggers Fc-mediated effector functions, and provides significant protection against SARS and COVID-19 disease in mouse models. Thus, ADG-2 represents a promising candidate for the prevention and treatment of not only COVID-19 but also future respiratory diseases caused by pre-emergent SARS-related CoVs. Furthermore, our fine epitope mapping and structural studies demonstrate that ADG-2 employs a unique angle of approach to recognize a highly conserved epitope overlapping the receptor binding site. This epitope represents an Achilles’ heel for clade 1a and 1b sarbecoviruses and hence an attractive target for the rational design of “pan-SARS” vaccines that aim to elicit similar broadly protective antibodies.</p>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary information</label>
<media xlink:href="EMS107254-supplement-Supplementary_information.pdf" mimetype="application" mime-subtype="pdf" id="N66640" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S1">
<title>Acknowledgements</title>
<p>We thank T. Boland for assistance with SARS-CoV-2 sequence analysis and C. Williams for assistance with figure preparation. We thank E. Krauland and M. Vasquez for helpful comments on the manuscript. We thank J. Ludes-Meyers for assistance with cell transfection. All IgGs were sequenced by Adimab's Molecular Core and produced by the High Throughput Expression group. BLI binding experiments were performed by Adimab's Protein Analytics group. Opinions, conclusions, interpretations, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. The mention of trade names or commercial products does not constitute endorsement or recommendation for use by the Department of the Army or the Department of Defense.</p>
<sec id="S2">
<title>Funding</title>
<p>This work was funded in part by National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) grants awarded to J.S.M (R01-AI12751), D.N. (R01-AI132317 and R01-AI073148), and R.S.B. (RO1-AI132178 and U54 CA260543). J.E.V. was also supported by the Bill and Melinda Gates Foundation (OPP 1183956). B.M.G. and J.M.D. were supported by NIH/NIAID grant 5U19AI142777.</p>
</sec>
</ack>
<sec id="S3" sec-type="data-availablity">
<title>Data and material availability</title>
<p id="P18">IgGs are available from the corresponding author under MTA from Adagio Therapeutics, Inc.</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P19">
<bold>Author contributions:</bold> L.M.W., L.E.G. and R.S.B conceived and designed the study. L.M.D. and J.B. performed the directed evolution experiments. L.V.T., D.H., A.S.H., C.M.O., L.P., L.Y., T.D.S., D.R.B., D.N., J.M.D., J.V. and R.S.B. developed, designed, and performed neutralization assays. M.E.B. and J.C.G. designed and supervised developability and biolayer interferometry assays. C.G.R., C.I.K., M.S., and M.B.B. designed and performed the yeast surface-display RBD experiments. D.W. and J.S.M. designed and performed Biacore SPR and structural assays. T.J.Y. and B.M.G. designed and performed Fc-effector functional assays. L.E.G. designed and performed the animal challenge studies. C.G.R., L.V.T., C.I.K., D.W., M.S., D.H., L.M.D., A.S.H., M.B.B., B.M.G., L.E.G., and L.M.W. analyzed the data. C.G.R., L.V.T., C.I.K., D.W., M.S. D.H., B.M.G., L.E.G., and L.M.W. wrote the manuscript and all authors reviewed and edited the paper.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P20">
<bold>Competing interests:</bold> C.G.R, C.I.K, M.S., L.M.D., M.B.B., M.E.B., J.C.G., and L.M.W.are employees of Adimab, LLC and may hold shares in Adimab, LLC. L.M.W. is an employee of Adagio Therapeutics Inc. and holds shares in Adagio Therapeutics Inc. D.R.B. is on the SAB of Adimab, LLC and Adagio Therapeutics Inc. and holds shares in Adimab, LLC.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
</person-group>
<article-title>Return of the Coronavirus: 2019-nCoV</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>NS</given-names>
</name>
<etal/>
</person-group>
<article-title>Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>362</volume>
<fpage>1353</fpage>
<lpage>1358</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaki</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>van Boheemen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bestebroer</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title>
<source>N Engl J Med</source>
<year>2012</year>
<volume>367</volume>
<fpage>1814</fpage>
<lpage>1820</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Memish</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Van</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Kerkhove Zumla</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Middle East respiratory syndrome</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>1063</fpage>
<lpage>1077</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<fpage>533</fpage>
<lpage>534</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>ZL</given-names>
</name>
</person-group>
<article-title>Origin and evolution of pathogenic coronaviruses</article-title>
<source>Nat Rev Microbiol</source>
<year>2019</year>
<volume>17</volume>
<fpage>181</fpage>
<lpage>192</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccoli</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corti</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2015</year>
<volume>112</volume>
<fpage>10473</fpage>
<lpage>10478</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rockx</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge</article-title>
<source>J Virol</source>
<year>2008</year>
<volume>82</volume>
<fpage>3220</fpage>
<lpage>3235</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion</article-title>
<source>Cell</source>
<year>2019</year>
<volume>176</volume>
<fpage>1026</fpage>
<lpage>1039</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wec</surname>
<given-names>AZ</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad neutralization of SARS-related viruses by human monoclonal antibodies</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>731</fpage>
<lpage>736</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>290</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<comment>2251</comment>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parren</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>The antiviral activity of antibodies in vitro and in vivo</article-title>
<source>Adv Immunol</source>
<year>2001</year>
<volume>77</volume>
<fpage>195</fpage>
<lpage>262</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wec</surname>
<given-names>AZ</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection</article-title>
<source>Cell Host Microbe</source>
<year>2019</year>
<volume>25</volume>
<fpage>39</fpage>
<lpage>48 e35</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldhaus</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library</article-title>
<source>Nat Biotechnol</source>
<year>2003</year>
<volume>21</volume>
<fpage>163</fpage>
<lpage>170</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giroglou</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein</article-title>
<source>J Virol</source>
<year>2004</year>
<volume>78</volume>
<fpage>9007</fpage>
<lpage>9015</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>120</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sievers</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AP</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Bjorkman</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Antibody engineering for increased potency, breadth and half-life</article-title>
<source>Curr Opin HIV AIDS</source>
<year>2015</year>
<volume>10</volume>
<fpage>151</fpage>
<lpage>159</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shehata</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability</article-title>
<source>Cell Rep</source>
<year>2019</year>
<volume>28</volume>
<fpage>3300</fpage>
<lpage>3308 e3304</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>TF</given-names>
</name>
<etal/>
</person-group>
<article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>956</fpage>
<lpage>963</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korber</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>812</fpage>
<lpage>827 e819</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310 e1220</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title>
<source>Nat Microbiol</source>
<year>2020</year>
<volume>5</volume>
<fpage>562</fpage>
<lpage>569</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>McCauley</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>GISAID: Global initiative on sharing all influenza data - from vision to reality</article-title>
<source>Euro Surveill</source>
<year>2017</year>
<volume>22</volume>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1014</fpage>
<lpage>1018</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>630</fpage>
<lpage>633</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunn</surname>
<given-names>BM</given-names>
</name>
<etal/>
</person-group>
<article-title>A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus</article-title>
<source>Cell Host Microbe</source>
<year>2018</year>
<volume>24</volume>
<fpage>221</fpage>
<lpage>233 e225</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice</article-title>
<source>PLoS Pathog</source>
<year>2007</year>
<volume>3</volume>
<fpage>e5</fpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>
<article-title>A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Simeonov</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2</article-title>
<source>Trends Pharmacol Sci</source>
<year>2020</year>
<volume>41</volume>
<fpage>815</fpage>
<lpage>829</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool</article-title>
<source>Protein Eng Des Sel</source>
<year>2013</year>
<volume>26</volume>
<fpage>663</fpage>
<lpage>670</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Biophysical properties of the clinical-stage antibody landscape</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2017</year>
<volume>114</volume>
<fpage>944</fpage>
<lpage>949</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarzotti-Kelsoe</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1</article-title>
<source>J Immunol Methods</source>
<year>2014</year>
<volume>409</volume>
<fpage>131</fpage>
<lpage>146</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>YJ</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>429</fpage>
<lpage>446 e414</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy</article-title>
<source>MAbs</source>
<year>2014</year>
<volume>6</volume>
<fpage>483</fpage>
<lpage>492</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Narhi</surname>
<given-names>LO</given-names>
</name>
<name>
<surname>Razinkov</surname>
<given-names>VI</given-names>
</name>
</person-group>
<article-title>High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations</article-title>
<source>J Pharm Sci</source>
<year>2011</year>
<volume>100</volume>
<fpage>5126</fpage>
<lpage>5141</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estep</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>An alternative assay to hydrophobic interaction chromatography for highthroughput characterization of monoclonal antibodies</article-title>
<source>MAbs</source>
<year>2015</year>
<volume>7</volume>
<fpage>553</fpage>
<lpage>561</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livingstone</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation</article-title>
<source>Comput Appl Biosci</source>
<year>1993</year>
<volume>9</volume>
<fpage>745</fpage>
<lpage>756</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carragher</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Leginon: an automated system for acquisition of images from vitreous ice specimens</article-title>
<source>J Struct Biol</source>
<year>2000</year>
<volume>132</volume>
<fpage>33</fpage>
<lpage>45</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tegunov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Real-time cryo-electron microscopy data preprocessing with Warp</article-title>
<source>Nat Methods</source>
<year>2019</year>
<volume>16</volume>
<fpage>1146</fpage>
<lpage>1152</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punjani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fleet</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Brubaker</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title>
<source>Nat Methods</source>
<year>2017</year>
<volume>14</volume>
<fpage>290</fpage>
<lpage>296</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punjani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fleet</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Non-uniform refinement: Adaptive regularization improves single particle cryo-EM reconstruction</article-title>
<source>bioRxiv</source>
<year>2019</year>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodwin</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation</article-title>
<source>Immunity</source>
<year>2018</year>
<volume>48</volume>
<fpage>339</fpage>
<lpage>349 e335</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<etal/>
</person-group>
<article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>
<source>J Comput Chem</source>
<year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<etal/>
</person-group>
<article-title>Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis</article-title>
<source>mBio</source>
<year>2018</year>
<volume>9</volume>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Engineering of SARS-CoV-2 antibodies for enhanced neutralization breadth and potency. <bold>(A)</bold> Flow cytometry plots from the terminal round of selection showing binding of parental antibodies (light blue) and affinity maturation library antibodies (dark blue) to the SARS-CoV-2 S1 protein at 1 nM. Gates indicate the yeast populations sorted for antibody sequencing and characterization. <bold>(B)</bold> Dot plots of Fab binding affinities (left) and MLV-SARSCoV-2 pseudovirus neutralization IC<sub>50</sub>s (right) of parental antibodies and affinity matured progeny. SARS-CoV-2 clinical antibodies are shown for comparison. <bold>(C)</bold> Heat map showing the neutralization IC<sub>50</sub>s of the indicated antibodies against authentic SARS-CoV, WIV-1-nLuc, SHC014-nLuc, SARS-CoV-2-nLuc, and SARS-CoV-2 using either HeLa-hACE2 or Vero target cells. SARS-CoV assays were performed on Vero cells. WIV-1-nLuc, SHCO14-nLuc, and SARS-CoV-2 nLuc assays were performed on Vero cells with recombinant, reverse geneticsderived viruses encoding a nano-luciferase reporter gene. <bold>(D)</bold> Authentic SARS-CoV-2 neutralization titrations performed using either HeLa-hACE2 (left) or Vero (right) target cells. The curves were fit by nonlinear regression. Error bars represent standard deviation. N.D., not determined; N.N., non-neutralizing.</p>
</caption>
<graphic xlink:href="EMS107254-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Breadth of antibody binding to diverse sarbecoviruses and circulating SARS-CoV-2 variants. <bold>(A)</bold> Phylogenetic tree of 57 sarbecoviruses constructed via MAFFT and maximum likelihood analysis of RBD-SD1 amino acid sequences extracted from the European Nucleotide Archive and GISAID database. Representative sarbecovirus RBDs selected for further study are denoted in bold and colored according to their canonical phylogenetic lineages. <bold>(B)</bold> Heat map of antibody and recombinant hACE2 binding to yeast-displayed RBDs from 17 representative sarbecoviruses, grouped by phylogenetic lineages. K<sub>D</sub>
<sup>App</sup> values were calculated by normalized nonlinear regression fitting. <bold>(C)</bold> Antibody binding to naturally-occurring SARS-CoV-2 RBD variants displayed on the surface of yeast. SARS-CoV-2 sequences were retrieved from the GISAID database on July 14, 2020 (<italic>n</italic> = 63551). Antibody binding signal was normalized to RBD expression and calculated as percent binding of the variant relative to the WT SARS-CoV2 RBD, assessed at their respective K<sub>D</sub>
<sup>App</sup> concentrations for the WT construct. The prevalence of each variant, calculated from deposited sequences on October 19, 2020 (<italic>n</italic> = 148115), is shown as a percentage of the total number of sequences analyzed. <bold>(D)</bold> Correlation between the number of resistant SARS-CoV-2 variants and percentage of clade I sarbecovirus RBDs recognized. N.B., non-binder.</p>
</caption>
<graphic xlink:href="EMS107254-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>ADG-2 binds to an evolutionarily conserved epitope on the SARS-CoV-2 RBD overlapping with the hACE2 binding site. <bold>(A)</bold> Schematic showing the generation and selection of a mutagenized, yeast surface-displayed SARS-CoV-2 RBD library to identify mutations that knock-down ADG-2 binding. <bold>(B)</bold> Heat map showing mutations that abrogate binding of ADG-2 to the SARS-CoV-2 RBD. S309 and CR3022, which bind non-overlapping epitopes distinct from the ADG-2 binding site, are included to control for mutations that globally disrupt the conformation of the RBD. Values indicate percent antibody or recombinant hACE2-Fc binding to the mutant SARS-CoV-2 RBD relative to the WT SARS-CoV-2 RBD, assessed at their respective EC<sub>80</sub> concentrations for the WT RBD construct. <bold>(C)</bold> Protein sequence alignment of representative sarbecovirus RBDs with sequences colored by percentage sequence identity and conservation shown as a bar plot. Positions delineating the receptor binding motif are based on the SARS-CoV-2 RBD. Residues determined to be important for ADG-2 binding based on the data shown in (B) are denoted in red. <bold>(D)</bold> Cryo-EM reconstruction of the SARS-CoV-2 RBD bound by ADG-2, with ADG-2 knock-down mutations and the hACE2 binding site highlighted in blue and red, respectively. <bold>(E)</bold> Structures of previously reported antibodies (bold) representing frequently observed SARS-CoV-2 nAb classes 1-4 overlaid on the ADG-2 structure (D), with additional representative SARS-CoV-2 nAbs listed.</p>
</caption>
<graphic xlink:href="EMS107254-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>ADG-2 triggers Fc-mediated effector functions. The indicated antibodies were assessed for the ability to induce Fc-mediated effector functions against RBD-coated targets at varying concentrations. <bold>(A)</bold> Primary human NK cells were analyzed for surface expression of CD107a, indicating degranulation (left), and the production of IFNγ (middle) or TNFα (right) following incubation with antibody-RBD immune complexes for 5 hours. <bold>(B)</bold> Antibodymediated phagocytosis of RBD-coated fluorescent beads by differentiated HL-60 neutrophils (left) or THP-1 monocytes (right) was measured following incubation with immune complexes for 18 hours. <bold>(C)</bold> Antibody-mediated complement deposition was measured by detection of complement component C3 onto RBD-coated fluorescent beads following incubation of guinea pig complement with immune complexes for 20 minutes.</p>
</caption>
<graphic xlink:href="EMS107254-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Prophylactic and therapeutic administration of ADG-2 protects mice from SARS-CoV- and SARS-CoV-2-associated viral diseases. Efficacy of prophylactic treatment with ADG-2 in <bold>(A)</bold> SARS-CoV-MA15 and <bold>(B)</bold> SARS-CoV-2-MA10 challenge models. A single dose of ADG-2 or sham treatment were delivered intraperitoneally 12 hours prior to infection. Mouse body weight and respiratory function were monitored for 4 days. Gross lung hemorrhage scores were determined on day 2 (MA15) or day 4 (MA10) post-infection and lung viral titers were measured on day 2 and day 4 post-infection. <bold>(C)</bold> Therapeutic treatment with ADG-2 or sham treatment at 12 hours post-SARS-CoV-2-MA10-infection. Mouse body weight, respiratory function, gross hemorrhage scores (day 2), and lung viral titers (days 2 and 4) were assessed as described above. Statistical comparisons were made using Mann-Whitney U tests or two-sided t-tests with Holm-Sidak corrections for multiple comparisons (*P &lt;0.05, **P &lt;0.01; ***P &lt;0.001). Dotted lines indicate the limit of detection.</p>
</caption>
<graphic xlink:href="EMS107254-f005"/>
</fig>
</floats-group>
</article>
